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Background and aims: The total health care cost for human immunodeficiency virus (HIV) 
patients has constantly grown in recent years. To date, there is no information about how this 
trend will behave over the next few years. The aim of the present study is to define a pharmaco-
economic model for the forecast of the costs of a group of chronically treated patients followed 
over the period 2004–2009.
Methods: A pharmacoeconomics model was built to describe the probability of transition among 
different health states and to modify the therapy over time. A Markov model was applied to 
evaluate the temporal evolution of the average cost. The health care resources exploited during 
hospitalization were analyzed by using an “activity-based costing” method.
Results: The Markov model showed that the mean total cost, after an initial increase, tended 
to remain stable. A total of 20 clinical records were examined. The average daily cost for each 
patient was EUR 484.42, with a cost for admission of EUR 6781.88.
Conclusion: The treatment of HIV infection in compliance with the guidelines is also effective 
from the payer perspective, as it allows a good health condition to be maintained and reduces 
the need and the costs of hospitalizations.
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Introduction
Out of the nearly 150,000 people who live with human immunodeficiency virus (HIV) 
infection in Italy, about 25,000 have full-blown disease. Although the epidemiologic 
trend of HIV infection shows a significant decrease, a small but constant number of 
new cases is diagnosed every year.1
Since 1996, highly active antiretroviral therapy (HAART) has changed the 
clinical course of HIV infection, reducing the rate of disease progression, incidence 
of opportunistic infections, and mortality. This prolonged survival has turned HIV 
infection into a chronic disease. This change has caused a constant shift of the economic 
resources needed to treat HIV infection from the hospital to outpatient management. 
The economic impact of HIV infection is well acknowledged, and it mainly includes 
the use of health care services for the treatment of HIV infection, the treatment of 
acquired immunodeficiency syndrome (AIDS)-associated symptoms and opportunistic 
infections, and the indirect costs associated with morbidity and premature death of 
working-age patients.2,3
In Italy, inpatient and outpatient specialist services are funded according to a 
prospective per case payment system based on a regional fee plan. The reimbursement 
provided for outpatient activities is based on national price lists. Each region can 
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choose whether to adopt the national rate of reimbursement 
or determine its own rate, as in the case of the Lombardy 
Regional Healthcare System (RHS). This is calculated taking 
into account the production costs (time and resources) and 
the strategic priorities of the Regional Social Services and 
Health Care Plan, which are updated yearly.4
The amount to be paid by the RHS for hospital admissions 
is determined using the diagnosis-related group (DRG) 
system (International Classification of Diseases, Ninth 
Revision, Clinical Modification), introduced in Italy in 1995. 
A specific weight, which takes into account the composition 
of the procedures delivered by the providers, is assigned to 
each region and updated every year. Such weight is used 
to calculate the regional diagnosis-related group rate of 
reimbursement.
The Lombardy region is the most populated of the 
20 Italian regions, with more than 15% of the whole Italian 
population, and has the highest prevalence of AIDS cases 
in Italy, which has a strong impact on the regional health 
care budget.
From 2001 to 2008, there have been more than 3500 new 
HIV cases diagnosed in Lombardy, with a high prevalence 
(70%) within males. The majority of patients were diagnosed 
with an advanced phase of the disease.4 Recently, the health 
authorities of the Lombardy region organized a survey aimed 
at the characterization of the epidemiological features of 
new HIV cases. A total of 472 new HIV subjects have been 
identified showing a high prevalence of heterosexual exposure 
as a risk factor. These epidemiological data confirm that 
facing HIV remains a priority for health care organizations 
and that a specific strategy needs to be implemented.2
In Lombardy, HAART therapies can be delivered only 
inside the hospitals. The provider is refunded with the same 
amount the RHS paid at the moment of the purchase of each 
drug. As also reported in international studies, this amount 
is generally lower than the market value.4
Up to now, the Regional Healthcare Service has spent 
more than EUR 150,000,000 to provide HIV therapy, and this 
amount increases by about 10% every year. In Lombardy, the 
total number of treated patients increased by 32.1% between 
2004 and 2009. The total expenditure for the management 
of these subjects increased from EUR 224,902,421 to EUR 
255,946,864, mostly due to the cost of the drugs, which grew 
from EUR 107,185,600 to EUR 137,215,086 (data from the 
Regional Data Base: banca Dati assistito Regione Lombardia). 
Previous studies have investigated the determinants of costs, 
consistently finding a relationship between CD4 cell count 
and health care expenditures.5
As a matter of fact, other clinical features such as HIV 
viral load and hepatitis C virus coinfection may be related 
to costs. Moreover, although it has been shown that the total 
health care cost for these patients has constantly grown, 
there is still no information about how this trend will 
behave in the upcoming years, in particular with regards 
to chronically treated patients, who are the majority in the 
treated population.4
Since the expenditure for the care of patients with HIV 
AIDS has a relevant impact on the total health budget in Italy, 
and its trend is currently unknown, the present study was 
designed to define a pharmacoeconomic model to forecast the 
costs of a group of chronically treated patients followed over 
the period 2004–2009 at the Division of Infectious and Tropical 
Diseases of the IRCCS Policlinico San Matteo Foundation. 
Because the estimate of the real cost of hospital admission is 
currently not evaluated, an “activity-based costing” model was 
used to provide a trusted measure of resources employed in 
this setting. The combination of these data will supply a better 
resource allocation to the policymaker.
Methods
A pharmacoeconomic model, and in particular a Markov 
model (MM),6 was implemented to forecast the total 
expenditure trend over the next 4 years. MMs are stochastic 
models, where the study of a system is based on the 
assessment of the state of the system at a specific time stamp 
and of the probability of transition to a new state in the future, 
such transition being dependent only on the values of the 
current state and not on the previous history of the system 
up to that point (Markov property).
The six health care states of the MM were defined based 
on CD4 count and HIV viral load, as detailed in Table 1. 
Such a model takes into account the probability of:
•	 transition among different health states over time;
•	 modification of the therapy due to virological failure or 
side effects; and
•	 use of new generation and expensive drugs.
Table 1 Health state subdivision according to CD cell count and 
HIV-viral load
Health state CD4 cell count Viral load
1 ,350 .50
2 ,350 ,50
3 350–500 .50
4 350–500 ,50
5 .500 .50
6 .500 ,50
Abbreviation: CD, cluster of differentiation.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
118
Sacchi et alClinico Economics and Outcomes Research 2012:4
This model will enable the number of people who will be in 
a specific health status at a particular time to be determined. 
As the total health care costs increase with the progression 
of the disease, the probability for a patient to change his/her 
health status will influence the total cost of the patient 
group he/she belongs to, and consequently will be related to 
the definition of the total resources to be employed for the 
management of the patients.
This model has been implemented using TreeAge Pro Suite 
software (TreeAge Software, Inc, Williamstown, MA).
To build the model, an evaluation of the clinical records of 
the patients treated at the Division of Infectious and Tropical 
Diseases between 2004 and 2009 was carried out. For each 
patient, the following data were collected:
•	 demographics, clinical events, antiretroviral therapy;
•	 the total cost, calculated as a sum of:
○	 antiretroviral drugs cost (number of boxes per month 
of treatment),
○	 visits cost,
○	 laboratory and instrumental examinations cost 
(according to the price list of RHS for Lombardy),
○	 nonantiretroviral therapy cost (all the drugs pre-
scribed to the patient and collected at any provider 
within the Lombardy region, such as hospitals and 
pharmacies),
○	 hospital admissions cost (DRGs reimbursement).
Costs were discounted at 2009, considering the Italian infla-
tion rates related to the average consumer prices. Cost analyses 
were performed considering both the evolution of the total 
costs and of each cost category between 2004 and 2009. The 
clinical data were then analyzed to identify patient character-
istics which may be related to the costs in each year.
The cohort of HIV patients followed at the outpa-
tients division of the Divisione di Malattie Infettive e 
Tropicali - Fondazione IRCCS Policlinico San Matteo, Pavia 
was analyzed separately.
Activity-based cost of HIV-related DRGs
The analysis of the resources exploited for the assistance 
of patients during hospitalization (eg, the actual amount of 
direct costs and the estimate of indirect costs) was carried 
out by a retrospective analysis of the clinical records of 20 
cases. The “activity-based costing” method was used, which 
is an accounting method that analyzes the performance 
process by breaking it down into multiple activities and 
computing the final cost as the sum of the cost of each 
activity. The cost of health performances can be divided into 
all the components cooperating in the production process.
The methodology used in this case was as follows:
1.  Modeling of the process of care, taking into account the 
sequence of diagnosis, therapy, and assistance given to 
the hospitalized patient
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General cost:
Internal logistic
Management of nonhealth material
Sanitation
Maintenance cost of equipment
Administrative check in/out
Indirect
cost
Laundry
Medical care
Patient cost
Meal
Health material,
drug, etc
Medical laboratory
instrumental
tests/procedures
Daily
hospitalization
Figure 1 Matrix used for activity-based cost evaluation.
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Description
Financial
statement
at 4th
trimester
2009 mg tot mg 242
Day total
hospitalized
Total for day
hospitalized
Meal cost
for
patient
Meal cost
employee
Employee
24_2
Turnover
cost
Hospitalized
day 24_2
Total
mg
Laundry 561,000
164,996 12.431 ,331.59
0.411
308,254 1819.93
6.17 8.411
5.39 37
15,307.41
16,552.44
103,791.74
43,455.55
4,438.74
7,303.75
34,033.04
4,616.29
1,089.51
391.70
329,4615.37
870,399.24
601,855.47
8,966.26
28,989.01
Total turnover cost
Total cost
Cost for day hospitalized
1,331.59
1,331.59
1,331.59
1,331.59
1,331.59
3.33
5.48
25.56
3.47
0.82
21.77
6.73
164,996
164,996
164,996
164,996
164,996
4,996
2051.000
0
0
2,651,000
326
21(13+8)
89
80
0
893
1.674
3,592,000
1,111,000
2000
550,000
905,000
4,217,000
572,000
135,000
0
Sanitation
Inpatient meals
Employee canteen
Heating
Data processing service
Not health transport
Garbage disposal
Phone use
Water. gas. combustible
Outside vigilance service
Other use
Insurance: other recompense
Purchase of nonhealth other service: sum
Mail service postal telex
Advertisement
Travel refund of expense
Other nonhealth use bought in “S”
Other nonhealth use
Combustible
Maintenance and ordinary repairs
General cost and administrative
equity 7.5% of direct cost
Insurance: Recompense for professional
Electricity use
Figure 2 Indirect cost categories and cost driver used for cost allocation.
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Figure 3 Trend of drug expenditure for the whole cohort of patients followed at site.
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Figure 4 Mean patient cost subdivided by year for the whole cohort of patients. Ratio: yearly cost/n patients.
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2.  Identification of the matrix of performed activities, 
including the knowledge on the professional figures 
involved. The following activities were identified:
•	 hospital admission (administrative, medical, and 
nursing)
•	 hospital stay (medical and nursing activity during 
hospital stay, meal and laundry costs, diagnostic 
procedures – both laboratory and instrumental, health- 
and nonhealth-related equipment costs, external 
consultants)
•	 hospital discharge (administrative, medical, and 
nursing)
A scheme of the root used is shown in Figure 1.
To quantify the cost of each activity, the following 
guidelines were used:
1.  Medical and nursing assistance (whole staff cost per day 
of stay)
2.  Direct cost of material and diagnostic procedures 
(cost/day or cost/activity – price list of RHS for 
Lombardy)
3.  Indirect costs (calculated according to hospital cost driver, 
as summarized in Figure 2).
Results
Cost of antiretroviral therapy  
in the period 2004–2009
This analysis was carried out on the total cohort of patients 
followed at the authors’ department. During the monitored 
period, the total drug cost constantly increased both as a 
whole cost and as percentage trend. Figure 3 shows how the 
yearly incremental cost is about 17% for years 2005–2006, 
decreases to 5% for 2007–2008, and goes back to previous 
levels for 2008–2010. This trend is motivated by the increase 
in the number of treated patients (from 840 to 913 during the 
observation period) and by the use of more expensive drugs 
as suggested by the simultaneous growth of the average cost 
per patient (Figure 4).
Analysis of a cohort of 200 patients
Demographics
A total of 200 subjects consecutively starting the follow-up 
period between 2004 and 2009 were considered for the 
analysis. Table 2 summarizes the demographic features of 
the analyzed population. All patients received antiretroviral 
treatment during their follow-up.
Costs according to health state
Table 3 shows the distribution of the patients according to 
their health status. At the beginning of the observation period, 
the percentage of patients in state 1 was 37%, while in 2009 it 
dropped to 9%. At the same time, the percentage of patients in 
state 6 rose from 8% in 2004 to 27% in 2009, with an increase 
of 5% every year. Table 4 reports the detailed costs related 
to the different considered categories, such as drugs, visits, 
and laboratory and instrumental tests. The total cost of each 
status and the average cost per patient are also reported. The 
transition of patients towards a better health status affects 
the overall cost distribution, while the average yearly cost 
per patient remains quite stable. The total cost of patients in 
Table 2 Demographic characteristics of patients analyzed by the 
Markov model (200 subjects)
Characteristic Value
Sex
  Male 67%
  Female 33%
Risk factor
  Heterosexual 44.5%
  MSM 7.5%
  IVDA 48%
CD4 nadir mean (cell/mm3) 174
HCV positive 45%
Mean age 47 years
Abbreviations:  CD,  cluster  of  differentiation;  HCV,  hepatitis  C  virus;  IVDA, 
intravenous drug abuse; MSM, men who have sex with men.
Table 3 Subdivision of patients according to health status
Health state CD4 VL 2004 2005 2006 2007 2008 2009
N % N % N % N % N % N %
1 ,350 .50 74 37% 45 23% 32 16% 20 10% 16 8% 17 9%
2 ,350 ,50 36 18% 43 22% 41 21% 27 14% 28 14% 22 11%
3 350–500 .50 26 13% 24 12% 25 13% 27 14% 20 10% 15 8%
4 350–500 ,50 35 18% 47 24% 55 28% 54 27% 47 24% 53 27%
5 .500 .50 9 5% 9 5% 9 5% 5 3% 7 4% 6 3%
6 .500 ,50 15 8% 20 10% 32 16% 45 23% 53 27% 53 27%
Abbreviations: CD, cluster of differentiation; VL, viral load.
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Figure 5 Health state 1: cost trend 2004–2009.
state 1 decreased from EUR 328,171 (2004) to EUR 110,311 
(2009), with an average cost per patient ranging from EUR 
5164 (2004) to EUR 6489 (2009) (Figure 5). With regards to 
state 6, its cost increases from EUR 80,099 in 2004 to EUR 
400,374 in 2009. This is associated also with an increase in 
the average cost per patient, which rose from EUR 5340 to 
EUR 7554 (Figure 6).
Analysis of the cost trend as forecasted by the MM
The analysis of the costs performed through an MM shows 
that patients have a high probability to move to a better 
health status along the period of observation (Figure 7), 
while the average total cost, after an initial increase, tends 
to show a stable behavior (Figure 8). This observation is 
confirmed also by a Monte Carlo simulation (Figure 9) 
showing that in a hypothetical cohort of 10,000 patients, 
the average cost per patient for the period 2004–2013 
would range between EUR 72,000 and EUR 76,000, 
with a probability of more than 50% (Figure 10) (95% 
uncertainty limits, calculated by taking the 2.5th and 
97.5th percentiles of the 10000 Monte Carlo simulations: 
[53568.17, 83865.63]).
Table 4 Cost analysis for every health status, split by year Table 4 (Continued)
Health  
state
2004 2005 2006 2007 2008 2009
N Tot cost (€) Mean N Tot cost (€) Mean N Tot cost (€) Mean N Tot cost (€) Mean N Tot cost (€) Mean N Tot cost (€) Mean
1 74.00 382,171.27 5,164.48 45.00 274,599.00 5,502.20 32.00 193,272.00 6,039.75 21.00 133,186.00 6,342.19 16.00 82,085.00 5,130.31 17.00 110,311.00 6,488.88
2 36.00 238,506.17 6,625.17 43.00 329,152.00 7,654.70 41.00 606,646.00 14,796.24 27.00 229,504.00 8,500.15 28.00 318,407.00 11,371.68 22.00 187,735.00 8,533.41
3 26.00 58,233.00 2,239.73 24.00 78,158.00 3,256.58 25.00 111,354.00 4,454.16 26.00 103,631.00 3,985.81 20.00 107,440.00 5,372.00 15.00 71,830.00 4,788.67
4 35.00 212,028.00 6,057.94 47.00 307,471.00 6,541.94 55.00 366,930.00 6,671.45 54.00 388,111.00 7,187.24 47.00 364,825.00 7,762.23 53.00 371,451.00 7,008.49
5 9.00 30,680.00 3,408.89 9.00 24,082.00 2,675.78 9.00 33,073.00 3,674.78 5.00 13,950.00 2,790.00 7.00 25,738.00 3,676.86 6.00 25,204.00 4,200.67
6 15.00 80,099.00 5,339.33 20.00 129,832.00 6,491.60 32.00 216,111.00 6,753.47 45.00 339,419.00 7,542.64 53.00 438,954.00 8,282.15 53.00 400,374.00 7,554.23
Total 195.00 1,001,717.4 188.00 1,116,294.0 194.00 1,527,386.00 178.00 1,207,801.0 171.00 1,337,449.0 166.00 1,166,904.0
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Figure 6 Health state 6: cost trend 2004–2009.
Table 4 Cost analysis for every health status, split by year Table 4 (Continued)
Health  
state
2004 2005 2006 2007 2008 2009
N Tot cost (€) Mean N Tot cost (€) Mean N Tot cost (€) Mean N Tot cost (€) Mean N Tot cost (€) Mean N Tot cost (€) Mean
1 74.00 382,171.27 5,164.48 45.00 274,599.00 5,502.20 32.00 193,272.00 6,039.75 21.00 133,186.00 6,342.19 16.00 82,085.00 5,130.31 17.00 110,311.00 6,488.88
2 36.00 238,506.17 6,625.17 43.00 329,152.00 7,654.70 41.00 606,646.00 14,796.24 27.00 229,504.00 8,500.15 28.00 318,407.00 11,371.68 22.00 187,735.00 8,533.41
3 26.00 58,233.00 2,239.73 24.00 78,158.00 3,256.58 25.00 111,354.00 4,454.16 26.00 103,631.00 3,985.81 20.00 107,440.00 5,372.00 15.00 71,830.00 4,788.67
4 35.00 212,028.00 6,057.94 47.00 307,471.00 6,541.94 55.00 366,930.00 6,671.45 54.00 388,111.00 7,187.24 47.00 364,825.00 7,762.23 53.00 371,451.00 7,008.49
5 9.00 30,680.00 3,408.89 9.00 24,082.00 2,675.78 9.00 33,073.00 3,674.78 5.00 13,950.00 2,790.00 7.00 25,738.00 3,676.86 6.00 25,204.00 4,200.67
6 15.00 80,099.00 5,339.33 20.00 129,832.00 6,491.60 32.00 216,111.00 6,753.47 45.00 339,419.00 7,542.64 53.00 438,954.00 8,282.15 53.00 400,374.00 7,554.23
Total 195.00 1,001,717.4 188.00 1,116,294.0 194.00 1,527,386.00 178.00 1,207,801.0 171.00 1,337,449.0 166.00 1,166,904.0
Activity-based cost of HIV-related DRGs
Twenty clinical records of patients admitted to hospital 
in the first 6 months of 2009, among those of the group 
analyzed by MM, have been examined, each one referring 
to a single hospital stay. The computation of the costs for 
every admission showed that the indirect costs and those 
related to hospital staff total EUR 391.70. Figure 2 shows 
the strategy used to evaluate the costs. Into this amount, the 
cost of administrative and general activities that account for 
the 7.5% of the total direct cost were also considered. The 
direct cost for each patient is computed as the sum of the costs 
for drugs, laboratory tests, and procedures. The cost of the 
drugs was assessed by multiplying the number of dispensed 
units (pills or vials) for each day of stay by the length of 
stay. The mean length of stay was 14 days. The average daily 
cost for each patient was EUR 485.12 (EUR 391.70 indirect 
cost + EUR 93.42 direct cost), with an average cost per 
admission of EUR 6792.88 (Figures 10 and 11).
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Figure 7 Predicted probabilities for each health status (Markov probability analysis).
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Figure 9 Monte Carlo simulation.
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Figure 10 Activity-based cost: mean cost (in €) for a day of stay of 20 HIV hospitalized patients.
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Figure 11 Activity-based cost (€): mean cost for hospital admission of 20 HIV hospitalized patients.
Discussion
This retrospective study was designed to evaluate the temporal 
evolution of the resources used in HIV patient care. Since it is 
trivial that the increase in the number of treated patients should 
lead to an increase in the health care related costs, the authors 
herein tried to assess the costs of a cohort of chronically 
treated patients to forecast the amount of resources needed 
over the next few years to carry on their health assistance. This 
is particularly useful in a   setting where the public RHS has 
to make a regular plan of the amount of future costs. It was 
found that the costs relating to the cohort of patients treated 
at the authors’ institution increased   constantly over time. This 
is due to an increase in the number of treated patients and 
to the use of new and more expensive drugs. Focusing on a 
group of chronic patients treated for a long period of time, it 
was found that the costs remain substantially stable and will 
not show a significant growth in the future. Moreover, the 
patients are likely to show a transition toward a better health 
status. The advantages of the antiretroviral treatment are con-
firmed by the reduction of the hospitalization rate, shown by 
the decrease in the costs relating to the reimbursements for 
hospital admission. Also, it was also found that each day at 
the hospital costs about EUR 500. This amount exceeds the 
DRG reimbursement fee if the stay is longer than 13 days. 
Thus, hospitalization causes a resource use corresponding to 
that of a year of antiretroviral therapy.
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The data in this study are consistent with those presented 
in other studies that demonstrate that antiretroviral therapy is 
cost-effective.7 Schackman et al analyzed the composition of 
the total cost related to the treatment of HIV-positive patients 
in the United States. The main cost category was HAART, 
with a percentage impact of 73%, consistent with the findings 
of this present study. Fleishman et al,8 who analyzed the costs 
of outpatient visits and inpatients activities in more than 
13,000 HIV-infected adults between 2000 and 2002, found 
that the cost of inpatient activities decreased constantly during 
the period, whereas outpatient activities cost was more stable. 
Recently, a paper published by Rizzardini et al9 showed 
findings similar to the present study where it was observed 
that an increase in HAART percentage impacts on the total 
cost. These authors demonstrate also that age, lower CD4 
cell count, coinfection of hepatitis C virus and undetectable 
HIV-RNA are determinants of cost increase. These findings 
are very interesting, since they are related to an economic 
setting that is the same as that in the present study.
The present study has some limitations. First, it is a 
single-center study, and the results may be affected by local 
patient management and by the use of considered cost driver. 
Moreover, the number of patients is limited and cannot be 
considered representative of a wider sample. Finally, the 
different reimbursement systems within the National Health 
Service make the results of this study not directly comparable 
to those of other international studies.
Our findings should however address some indication to 
the payer. First, the treatment of patients in a stable clinical 
condition doesn’t show a trend leading to a significant 
increase. Second, also treating patients in an early stage of 
the disease allows them to be maintained in a good condition, 
reducing the need of hospitalization. Third, the hospital 
stay requires the use of massive economic resources, which 
increase with the length of hospitalization and exceed the 
reimbursement fee. Finally, the tendency to an improvement 
of the patients’ condition opens the way to a reduction of the 
nontangible costs related to HIV disease, such as productivity 
loss and the worsening of quality of life.
In conclusion, it can be stated that the treatment of HIV 
infection in compliance to the guidelines is effective also from 
the payer perspective, as it allows maintaining a good health 
condition and reducing the need and the costs of hospital-
izations. This is particularly important where the resources 
appointed to the in-hospital care are planned to be reduced 
toward the use for home care strategies. Because the total 
expenditure for antiretroviral drugs in Italy follows only that 
for anticancer ones, the forecasting of how much the trend 
will increase is crucial to better allocate the financial resources 
needed to treat patients with this transmissible disease. Since 
the patients actually treated are in a stable condition, the focus 
of this study was on this category of subjects because they use 
the largest amount of resources. The finding of a stability of 
expenditure trend in these subjects, with a forecast extended 
until 2013, allows policymakers to plan a better allocation of 
health care resources, by putting new resources toward the 
treatment of newly diagnosed patients and new strategies 
of care, such as that of simplification of therapy, and, more 
importantly, to prevent the spread of the disease.
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